HER3 PET Imaging Predicts Response to Pan Receptor Tyrosine Kinase Inhibition Therapy in Gastric Cancer

[1]  Y. Yen,et al.  Hyperpolarized [1-13C]Pyruvate Magnetic Resonance Spectroscopic Imaging for Evaluation of Early Response to Tyrosine Kinase Inhibition Therapy in Gastric Cancer , 2022, Molecular Imaging and Biology.

[2]  U. Mahmood,et al.  HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib , 2021, Molecular Imaging and Biology.

[3]  HER3 Differentiates Basal From Claudin Type Triple Negative Breast Cancer and Contributes to Drug and Microenvironmental Induced Resistance , 2020, Frontiers in Oncology.

[4]  Susumu Nakata,et al.  Efficacy of Afatinib and Lapatinib Against HER2 Gene-amplified Trastuzumab-sensitive and -resistant Human Gastric Cancer Cells , 2019, AntiCancer Research.

[5]  J. Mattes,et al.  MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells , 2019, PloS one.

[6]  J. Crown,et al.  Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer , 2019, Cancers.

[7]  G. V. van Dongen,et al.  Immuno-PET Imaging to Assess Target Engagement: Experience from 89Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors , 2019, The Journal of Nuclear Medicine.

[8]  M. Campone,et al.  Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer , 2018, Cancer Chemotherapy and Pharmacology.

[9]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[10]  J. Soh,et al.  Therapeutic strategies for afatinib‐resistant lung cancer harboring HER2 alterations , 2018, Cancer science.

[11]  J. Hasenauer,et al.  Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines , 2018, Molecular oncology.

[12]  U. Mahmood,et al.  Phage Display Selection, In Vitro Characterization, and Correlative PET Imaging of a Novel HER3 Peptide , 2018, Molecular Imaging and Biology.

[13]  E. D. de Vries,et al.  89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment , 2017, mAbs.

[14]  Allan Hackshaw,et al.  Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: A meta‐analysis , 2017, International journal of cancer.

[15]  Liwu Fu,et al.  Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma. , 2017, American journal of cancer research.

[16]  Joon-Oh Park,et al.  Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Baselga,et al.  Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance , 2016, The Journal of Nuclear Medicine.

[18]  Kenan Chen,et al.  HER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-Analysis , 2016, PloS one.

[19]  C. Scapulatempo-Neto,et al.  HER2 testing in gastric cancer: An update. , 2016, World journal of gastroenterology.

[20]  M. Welch,et al.  Phase 1 Evaluation of [64Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors , 2016, Molecular Imaging and Biology.

[21]  Kaoru Tanaka,et al.  The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer , 2015, Oncotarget.

[22]  V. Torri,et al.  Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas , 2015, Clinical Cancer Research.

[23]  A. Rustgi,et al.  Imaging of Secreted Extracellular Periostin, an Important Marker of Invasion in the Tumor Microenvironment in Esophageal Cancer , 2015, The Journal of Nuclear Medicine.

[24]  L. Sequist,et al.  Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. , 2015, The Lancet. Oncology.

[25]  U. Mahmood,et al.  Pharmacodynamic Imaging Guides Dosing of a Selective Estrogen Receptor Degrader , 2015, Clinical Cancer Research.

[26]  M. Yashiro,et al.  Recent advances in the HER2 targeted therapy of gastric cancer. , 2015, World journal of clinical cases.

[27]  Dan Zhu,et al.  Functional Genetic Approach Identifies MET, HER3, IGF1R, INSR Pathways as Determinants of Lapatinib Unresponsiveness in HER2-Positive Gastric Cancer , 2014, Clinical Cancer Research.

[28]  U. Mahmood,et al.  A container closure system that allows for greater recovery of radiolabeled peptide compared to the standard borosilicate glass system. , 2013, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[29]  Martin Clynes,et al.  A gene expression profile indicative of early stage HER2 targeted therapy response , 2013, Molecular Cancer.

[30]  Jason S. Lewis,et al.  Monitoring Afatinib Treatment in HER2-Positive Gastric Cancer with 18F-FDG and 89Zr-Trastuzumab PET , 2013, The Journal of Nuclear Medicine.

[31]  A. Viale,et al.  Relief of Feedback Inhibition of Her3 Transcription by Raf and Mek Inhibitors Attenuates Their Antitumor Effects in Braf -mutant Thyroid Carcinomas Human Oncology and Pathogenesis Program, Pathology, And , 2022 .

[32]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[33]  Dhara N. Amin,et al.  Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver , 2010, Science Translational Medicine.

[34]  S. Al-Batran,et al.  Chemotherapy for advanced gastric cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  K. Shokat,et al.  Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.

[36]  A. Petroianu,et al.  Modified therapy with 5‐fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer , 1993, Cancer.

[37]  R. Jensen,et al.  Characteristics of cell lines established from human gastric carcinoma. , 1990, Cancer research.